CLINICAL TRIALS PROFILE FOR LINZESS
✉ Email this page to a colleague
All Clinical Trials for Linzess
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00730171 ↗ | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Completed | Forest Laboratories | Phase 3 | 2008-09-01 | The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C). |
| NCT00730171 ↗ | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Completed | Ironwood Pharmaceuticals, Inc. | Phase 3 | 2008-09-01 | The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C). |
| NCT00765999 ↗ | An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Completed | Ironwood Pharmaceuticals, Inc. | Phase 3 | 2008-10-31 | The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C). |
| NCT00765999 ↗ | An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Completed | Forest Laboratories | Phase 3 | 2008-10-31 | The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C). |
| NCT01950403 ↗ | Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers | Completed | National Cancer Institute (NCI) | Phase 1 | 2013-09-01 | This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer. |
| NCT01950403 ↗ | Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers | Completed | Mayo Clinic | Phase 1 | 2013-09-01 | This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer. |
| NCT02220348 ↗ | A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically | Completed | Forest Laboratories | Phase 1 | 2014-07-31 | The purpose of this study is to determine the amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (72 μg, 145 μg, or 290 μg) in lactating women receiving the drug therapeutically. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Linzess
Condition Name
Clinical Trial Locations for Linzess
Trials by Country
Clinical Trial Progress for Linzess
Clinical Trial Phase
Clinical Trial Sponsors for Linzess
Sponsor Name
